Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy

Baslaim, Muna M.; Malik, Osama Al; Al-Sobhi, Saif S.; Ibrahim, Ezzeldin M.; Ezzat, Adnan; Ajarim, Dahish; Tulbah, Asma; Chaudhary, Mohammad A.; Sörbris, R

doi:10.1016/s0002-9610(02)00959-5

Cited by 36 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In locally advanced breast cancer treated with neoadjuvant chemotherapy, pathologic axillary nodal status differs from those of early breast cancer treated by upfront surgery [18]. Neoadjuvant chemotherapy might have modified the yield of involved axillary lymph nodes.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Keam

Kim

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Keam

Kim

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…This was the major limitation of our study. On the other hand, 39 patients who received neoadjuvant chemotherapy were not excluded from our study, which might have modified the nodal status in the axillary dissection [25]. …”

Section: Discussionmentioning

confidence: 99%

Does the Metastatic Lymph Node Ratio Influence the Disease-Free Survival of Patients with Breast Cancer: Single-Center Experiences

Ustaalioğlu¹,

Bılıcı²,

Kefeli³

et al. 2010

Oncology

View full text Add to dashboard Cite

Background: Axillary lymph nodes (ALNs) are the most important prognostic factor for survival in breast cancer. Pathological evaluation can affect the number of involved lymph nodes. In the current study, we evaluated whether the metastatic lymph node ratio (n ratio) is important in predicting disease-free survival (DFS) for breast cancer patients. Material and Methods: From 802 breast cancer cases, 427 patients with ALN metastasis were analyzed retrospectively. The n ratio was categorized as n ratio 1 (1–10%), n ratio 2 (10.01–50%) and n ratio 3 (>50%). DFS was established according to the Kaplan-Meier method. Predicting risk factors for relapse were analyzed using the Cox proportional hazards model. Results: The n ratio was significantly higher in breast cancer patients with advanced pathologic pT, pN and clinical stage, undifferentiated histology, lymphovascular and extracapsular invasion, more resected ALNs and positive progesterone receptor. In the univariate analysis, multicentricity, necrosis, grade, pN stage, estrogen receptor and progesterone receptor positivity, trastuzumab and neoadjuvant chemotherapy usage, the presence of inflammatory breast cancer and n ratio were found to be important factors in predicting DFS. Multivariate analysis indicated that multicentricity, neoadjuvant chemotherapy, trastuzumab usage and n ratio were significantly associated with prognosis. Conclusions: The n ratio is inexpensive, easily available and a simple prognostic factor for breast cancer patients with positive ALNs.

show abstract

“…Several studies have reported conflicting results on whether the number of axillary lymph nodes detected at ALND after completion of chemotherapy is lower than in patients undergoing surgery without neoadjuvant chemotherapy [39][40][41]. We recently reported a mean of 21.9 lymph nodes resected at ALND in patients after chemotherapy compared to a mean of 20.2 lymph nodes in the group undergoing surgery first [42].…”

Section: Axillary Lymph Node Count After Completion Of Chemotherapymentioning

confidence: 99%

Sentinel Lymph Node Biopsy After Chemotherapy

Jakub

Boughey

2011

Curr Breast Cancer Rep

View full text Add to dashboard Cite

The timing of sentinel lymph node (SLN) biopsy in patients receiving neoadjuvant chemotherapy remains a debated topic, despite increasing literature supporting use of SLN biopsy after chemotherapy. This article outlines the arguments for SLN biopsy prior to initiation of systemic therapy versus after neoadjuvant chemotherapy and the literature surrounding this debate. Additionally, special patient populations, including patients with inflammatory breast cancer and those presenting with node-positive disease, are discussed. SLN biopsy after completion of chemotherapy is accurate for axillary staging of patients with clinically node-negative axillas at presentation, except for those with inflammatory breast cancer.

show abstract

Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy

Cited by 36 publications

References 8 publications

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Does the Metastatic Lymph Node Ratio Influence the Disease-Free Survival of Patients with Breast Cancer: Single-Center Experiences

Sentinel Lymph Node Biopsy After Chemotherapy

Contact Info

Product

Resources

About